<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684851</url>
  </required_header>
  <id_info>
    <org_study_id>10-12-06B</org_study_id>
    <nct_id>NCT02684851</nct_id>
  </id_info>
  <brief_title>The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery</brief_title>
  <acronym>TXA</acronym>
  <official_title>The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carolinas Healthcare System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carolinas Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if patients undergoing acetabular ORIF (open
      reduction with internal fixation) who receive tranexamic acid have a reduced risk of
      allogenic blood transfusion, perioperative blood loss, wound complication and higher risk for
      thromboembolic events compared to patients who receive placebo. Investigators want to
      determine the cost-effectiveness related to allogenic blood transfusion as a blood loss
      management strategy in acetabular open reduction internal fixation (ORIF). Orthopaedic
      surgery carries with it a significant risk for blood loss. Current management of
      perioperative blood loss is the use of allogenic blood transfusion. Allogenic blood
      transfusion carries with it a risk for HIV and Hepatitis C as well as multiple adverse
      reactions. There have been significant efforts to reduce the use of allogenic blood
      transfusion in orthopaedic surgery. Tranexamic acid, an anti-fibrinolytic agent, has been
      used in management of blood during surgery. In order to determine the impact of tranexamic
      acid in reducing blood loss among patients undergoing acetabular ORIF, investigators will
      conduct a prospective randomized study. Patients undergoing acetabular surgery will be
      screened for this study. Patients will be then randomized to placebo or tranexamic acid which
      will be administered during and after surgery. The following data will be collected: patient
      characteristics, surgery information, blood loss, blood transfusions, wound complication
      within 30 days of surgery, and cost.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, investigators plan to prospectively determine the effect of tranexamic acid on
      blood loss and outcome after surgery to the acetabulum.

      Patients will be randomized into two groups. In this study, investigators plan to administer
      a 10mg/kg dose within 30 minutes of surgery followed by a 10mg/kg infusion over a 4hr period
      to the treatment group (for patients weighting over 100kg, a weight of 100kg will be used for
      the dose calculation). The control group will receive equal volumes of and rates of normal
      saline.

      Research Questions:

        1. Do patients undergoing acetabular ORIF who receive tranexamic acid have a reduced risk
           of allogenic blood transfusion as compared to patients who receive placebo?

        2. Do patients undergoing acetabular ORIF who receive tranexamic acid have reduced
           peri-operative blood loss as compared to patients who receive placebo?

        3. Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk
           for thromboembolic events than patients who receive placebo?

        4. Do patients undergoing acetabular ORIF who receive tranexamic acid have a reduced risk
           of wound complications (prolonged wound drainage, return to the OR within 30 days,
           infection)?

        5. Is the use of tranexamic acid cost effective relative to the use of allogenic blood
           transfusion as a blood loss management strategy in acetabular ORIF?
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Allogenic Blood Transfusions</measure>
    <time_frame>30 days</time_frame>
    <description>Do patients undergoing acetabular ORIF who receive tranexamic acid have a reduced risk of allogenic blood transfusion as compared to patients who receive placebo?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peri-operative blood loss</measure>
    <time_frame>30 days</time_frame>
    <description>Do patients undergoing acetabular ORIF who receive tranexamic acid have reduced peri-operative blood loss as compared to patients who receive placebo?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thromboembolic Events</measure>
    <time_frame>30 days</time_frame>
    <description>Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound complications</measure>
    <time_frame>30 days</time_frame>
    <description>Do patients undergoing acetabular ORIF who receive tranexamic acid have a reduced risk of wound complications (prolonged wound drainage, return to the OR within 30 days, infection)?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost</measure>
    <time_frame>30 days</time_frame>
    <description>Is the use of tranexamic acid cost effective relative to the use of allogenic blood transfusion as a blood loss management strategy in acetabular ORIF?</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Acetabular Fractures</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tranexamic acid: anti-fibrinolytic agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic acid: anti-fibrinolytic agents</description>
    <arm_group_label>Tranexamic</arm_group_label>
    <other_name>Tranexamic acid (anti-fibrinolytic agents )</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients aged 18 or above undergoing acetabular ORIF.

        Exclusion Criteria:

          -  All patients aged below 18 years undergoing acetabulum surgery

          -  Patients with color-blindness (color vision changes used to assess toxicity)

          -  Patients with subarachnoid hemorrhage.

          -  Patients with active intravascular coagulation.

          -  Patients with a previous history of venous thromboembolism or with a history of
             hypercoaguable conditions (i.e. Factor V Leiden, antiphospholipid antibody).

          -  Prisoners

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhav Karunakar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolinas Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Astedt B, Liedholm P, Wingerup L. The effect of tranexamic acid on the fibrinolytic activity of vein walls. Ann Chir Gynaecol. 1978;67(6):203-5.</citation>
    <PMID>742821</PMID>
  </reference>
  <reference>
    <citation>Benoni G, Fredin H, Knebel R, Nilsson P. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. Acta Orthop Scand. 2001 Oct;72(5):442-8.</citation>
    <PMID>11728069</PMID>
  </reference>
  <reference>
    <citation>Benoni G, Lethagen S, Fredin H. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res. 1997 Feb 1;85(3):195-206. Erratum in: hromb Res 1997 Oct 15;88(2):251.</citation>
    <PMID>9058494</PMID>
  </reference>
  <reference>
    <citation>Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand. 2000 Jun;71(3):250-4.</citation>
    <PMID>10919295</PMID>
  </reference>
  <reference>
    <citation>Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999 Jan;81(1):2-10.</citation>
    <PMID>9973048</PMID>
  </reference>
  <reference>
    <citation>Callaghan JJ, Spitzer AI. Blood management and patient specific transfusion options in total joint replacement surgery. Iowa Orthop J. 2000;20:36-45. Review.</citation>
    <PMID>10934623</PMID>
  </reference>
  <reference>
    <citation>Carson JL, Altman DG, Duff A, Noveck H, Weinstein MP, Sonnenberg FA, Hudson JI, Provenzano G. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion. 1999 Jul;39(7):694-700.</citation>
    <PMID>10413276</PMID>
  </reference>
  <reference>
    <citation>Claeys MA, Vermeersch N, Haentjens P. Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. Acta Chir Belg. 2007 Jul-Aug;107(4):397-401.</citation>
    <PMID>17966532</PMID>
  </reference>
  <reference>
    <citation>Clark CR. Perioperative blood management in total hip arthroplasty. Instr Course Lect. 2009;58:167-72.</citation>
    <PMID>19385529</PMID>
  </reference>
  <reference>
    <citation>Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest. 2009 Feb;135(2):513-520. doi: 10.1378/chest.08-2655. Review.</citation>
    <PMID>19201714</PMID>
  </reference>
  <reference>
    <citation>Ekbäck G, Axelsson K, Ryttberg L, Edlund B, Kjellberg J, Weckström J, Carlsson O, Schött U. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg. 2000 Nov;91(5):1124-30.</citation>
    <PMID>11049894</PMID>
  </reference>
  <reference>
    <citation>Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008 May 29;358(22):2319-31. doi: 10.1056/NEJMoa0802395. Epub 2008 May 14. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.</citation>
    <PMID>18480196</PMID>
  </reference>
  <reference>
    <citation>Garneti N, Field J. Bone bleeding during total hip arthroplasty after administration of tranexamic acid. J Arthroplasty. 2004 Jun;19(4):488-92.</citation>
    <PMID>15188109</PMID>
  </reference>
  <reference>
    <citation>Gill JB, Rosenstein A. The use of antifibrinolytic agents in total hip arthroplasty: a meta-analysis. J Arthroplasty. 2006 Sep;21(6):869-73.</citation>
    <PMID>16950041</PMID>
  </reference>
  <reference>
    <citation>Good L, Peterson E, Lisander B. Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth. 2003 May;90(5):596-9.</citation>
    <PMID>12697586</PMID>
  </reference>
  <reference>
    <citation>Gross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology. 1983 Mar;58(3):277-80.</citation>
    <PMID>6829965</PMID>
  </reference>
  <reference>
    <citation>Haynes RB, et al. Clinical Epidemiology: How to Do Clinical Practice Research. 3rd ed. Lippincott Williams and Wilkins, 2006.</citation>
  </reference>
  <reference>
    <citation>Husted H, Blønd L, Sonne-Holm S, Holm G, Jacobsen TW, Gebuhr P. Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients. Acta Orthop Scand. 2003 Dec;74(6):665-9.</citation>
    <PMID>14763696</PMID>
  </reference>
  <reference>
    <citation>Ido K, Neo M, Asada Y, Kondo K, Morita T, Sakamoto T, Hayashi R, Kuriyama S. Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties. Arch Orthop Trauma Surg. 2000;120(9):518-20.</citation>
    <PMID>11011672</PMID>
  </reference>
  <reference>
    <citation>Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop. 2005 Jun;76(3):314-9.</citation>
    <PMID>16156456</PMID>
  </reference>
  <reference>
    <citation>Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009 Mar;123(5):687-96. doi: 10.1016/j.thromres.2008.09.015. Epub 2008 Nov 12. Review.</citation>
    <PMID>19007970</PMID>
  </reference>
  <reference>
    <citation>Karunakar MA, Shah SN, Jerabek S. Body mass index as a predictor of complications after operative treatment of acetabular fractures. J Bone Joint Surg Am. 2005 Jul;87(7):1498-502.</citation>
    <PMID>15995116</PMID>
  </reference>
  <reference>
    <citation>Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet. 2007 Aug 4;370(9585):415-26. Review.</citation>
    <PMID>17679019</PMID>
  </reference>
  <reference>
    <citation>Muñoz M, García-Erce JA, Villar I, Thomas D. Blood conservation strategies in major orthopaedic surgery: efficacy, safety and European regulations. Vox Sang. 2009 Jan;96(1):1-13. doi: 10.1111/j.1423-0410.2008.01108.x. Review.</citation>
    <PMID>19121192</PMID>
  </reference>
  <reference>
    <citation>Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32.</citation>
    <PMID>21936146</PMID>
  </reference>
  <reference>
    <citation>Niskanen RO, Korkala OL. Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis. Acta Orthop. 2005 Dec;76(6):829-32.</citation>
    <PMID>16470437</PMID>
  </reference>
  <reference>
    <citation>Orpen NM, Little C, Walker G, Crawfurd EJ. Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients. Knee. 2006 Mar;13(2):106-10. Epub 2006 Feb 17.</citation>
    <PMID>16487712</PMID>
  </reference>
  <reference>
    <citation>Rajesparan K, Biant LC, Ahmad M, Field RE. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg Br. 2009 Jun;91(6):776-83. doi: 10.1302/0301-620X.91B6.22393.</citation>
    <PMID>19483232</PMID>
  </reference>
  <reference>
    <citation>Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM, Cremers S, Abraham IL; OSTHEO Investigation. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003 Apr;43(4):459-69.</citation>
    <PMID>12662278</PMID>
  </reference>
  <reference>
    <citation>Sadeghi M, Mehr-Aein A. Does a single bolus dose of tranexamic acid reduce blood loss and transfusion requirements during hip fracture surgery? A prospective randomized double blind study in 67 patients. Acta Medica Iranica 2007; 45: 437-42.</citation>
  </reference>
  <reference>
    <citation>Salido JA, Marín LA, Gómez LA, Zorrilla P, Martínez C. Preoperative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. J Bone Joint Surg Am. 2002 Feb;84-A(2):216-20. Erratum in: J Bone Joint Surg Am 2002 May;84-A(5):799.</citation>
    <PMID>11861727</PMID>
  </reference>
  <reference>
    <citation>Scannell BP, Loeffler BJ, Bosse MJ, Kellam JF, Sims SH. Efficacy of intraoperative red blood cell salvage and autotransfusion in the treatment of acetabular fractures. J Orthop Trauma. 2009 May-Jun;23(5):340-5. doi: 10.1097/BOT.0b013e31819f691d.</citation>
    <PMID>19390361</PMID>
  </reference>
  <reference>
    <citation>CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14.</citation>
    <PMID>20554319</PMID>
  </reference>
  <reference>
    <citation>Stulberg BN, Zadzilka JD. Blood management issues using blood management strategies. J Arthroplasty. 2007 Jun;22(4 Suppl 1):95-8.</citation>
    <PMID>17570287</PMID>
  </reference>
  <reference>
    <citation>Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011 Jan;93(1):39-46. doi: 10.1302/0301-620X.93B1.24984. Review.</citation>
    <PMID>21196541</PMID>
  </reference>
  <reference>
    <citation>Tornetta P 3rd. Displaced acetabular fractures: indications for operative and nonoperative management. J Am Acad Orthop Surg. 2001 Jan-Feb;9(1):18-28. Review.</citation>
    <PMID>11174160</PMID>
  </reference>
  <reference>
    <citation>Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplasty. 2006 Sep;21(6 Suppl 2):139-43.</citation>
    <PMID>16950076</PMID>
  </reference>
  <reference>
    <citation>Westrich GH, Sculco TP. Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone. J Bone Joint Surg Am. 1996 Jun;78(6):826-34.</citation>
    <PMID>8666599</PMID>
  </reference>
  <reference>
    <citation>Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, Samama CM, Molliex S. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology. 2006 Nov;105(5):1034-46. Review.</citation>
    <PMID>17065899</PMID>
  </reference>
  <reference>
    <citation>Zufferey PJ, Miquet M, Quenet S, Martin P, Adam P, Albaladejo P, Mismetti P, Molliex S; tranexamic acid in hip-fracture surgery (THIF) study. Tranexamic acid in hip fracture surgery: a randomized controlled trial. Br J Anaesth. 2010 Jan;104(1):23-30. doi: 10.1093/bja/aep314.</citation>
    <PMID>19926634</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carolinas Healthcare System</investigator_affiliation>
    <investigator_full_name>Madhav Karunakar</investigator_full_name>
    <investigator_title>Orthopaedic Traumatologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Antifibrinolytic Agents</mesh_term>
    <mesh_term>Fibrinolytic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>February 5, 2018</submitted>
    <returned>March 13, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

